# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001370053-24-000019
Filing Date
2024-04-24
Accepted
2024-04-24 16:05:50
Documents
8
Period of Report
2024-06-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | proxystatementfy2023_def14a.htm | DEF 14A | 806019
2 |  | anaptysbioproxycard_1.jpg | GRAPHIC | 1330105
3 |  | anaptysbioproxycard_2.jpg | GRAPHIC | 206627
4 |  | compensationvsnetincomev2.jpg | GRAPHIC | 78803
5 |  | compensationvstsrv2.jpg | GRAPHIC | 77560
6 |  | dfsignature.jpg | GRAPHIC | 4102
7 |  | johnorwinsignature.jpg | GRAPHIC | 5703
8 |  | newlogo.jpg | GRAPHIC | 50475
| Complete submission text file | 0001370053-24-000019.txt |  | 3220602

Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

EIN.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37985 | Film No.: 24870563
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)